Related Experiment Video
Updated: Jul 6, 2026
06:32
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
Maspin reduces prostate cancer metastasis to bone
Devon C Hall1, Teresa L Johnson-Pais, Barry Grubbs
1Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX 78229, USA.
Urologic Oncology
|March 28, 2008
Summary
Maspin, a tumor suppressor, significantly reduced bone metastasis in prostate cancer cells. However, it did not impact metastasis to other sites, suggesting a specific role in the bone microenvironment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metastasis Research
Background:
- Maspin, a serine protease inhibitor, normally suppresses tumor growth, angiogenesis, invasion, and metastasis.
- Reduced maspin expression is observed in breast and prostate cancers.
- Previous studies showed chromosome 18 introduction suppressed prostate cancer metastasis.
Purpose of the Study:
- To determine if maspin is the tumor/metastasis suppressor on chromosome 18.
- To investigate maspin's role in inhibiting bone metastasis when produced at endogenous levels.
Main Methods:
- Transfected PC-3 prostate cancer cells with a maspin-containing bacterial artificial chromosome (BAC).
- Assessed in vitro tumor suppressor phenotype.
- Evaluated in vivo bone metastasis reduction using an animal model.
Main Results:
- Maspin transfection into PC-3 cells resulted in an in vitro tumor suppressor phenotype.
- Significant reduction in the number and severity of skeletal metastases in BAC-transfected cells.
- Maspin did not affect metastasis to extra-skeletal sites.
Conclusions:
- Endogenous maspin expression inhibits skeletal metastasis in prostate cancer.
- Maspin likely plays a role in seeding or growth inhibition within the bone microenvironment.
- Maspin's effect on metastasis appears specific to bone, not distant sites.
